1. Home
  2. |Insights
  3. |Agency's Preclusionary (And Erroneous) "Revolving Door" Advice Provides Pre-Award Bid Protest Standing

Agency's Preclusionary (And Erroneous) "Revolving Door" Advice Provides Pre-Award Bid Protest Standing

Client Alert | 1 min read | 05.09.08

In The CNA Corporation v. United States (April 30, 2008)
the COFC granted standing to a potential bidder arguing that it would be effectively disqualified from a procurement because a key employee, a former NIH scientist, had received an agency ethics opinion finding applicable the life-long representational ban under criminal statute 18 U.S.C. 207(a)(1), thus precluding her from being assigned to the contract. In finding for the protester, the COFC held that (1) the agency's 15-page legal opinion was wrong because it misapplied the definition of "personal and substantial participation" required to trigger the life-long representational ban, and, further, (2) even if the agency's ethics opinion had been correct as to a representational ban, the scope of prohibited "representation" under the statute was not as broad as the agency's interpretation and the protester would have been able to use the former NIH employee as its principal investigator were it awarded the contract.

Insights

Client Alert | 7 min read | 09.14.26

AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development

Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage. ...